HyponatremiaLast Updated: March 13, 2002 |
Background: Hyponatremia is defined as a serum sodium concentration of less than 130 mEq/L. This is the most common electrolyte abnormality encountered in clinical practice, with an incidence of 1.5% of all pediatric hospital admissions. Symptoms and signs of hyponatremia are related to the absolute level and rate of fall of serum sodium from baseline. Symptoms do not correlate with specific sodium levels. However, symptoms may appear when the serum sodium concentration is less than 125 mEq/L. Understanding the pathophysiology and treatment options is important because the morbidity and mortality of untreated hyponatremia are significant.
Pathophysiology:
Causes
Three general mechanisms are as follows:
1. Deficiency in sodium intake
2. Excessive loss of sodium (renal or extrarenal)
3. Excessive water retention
Risk factors
Because the human body protects itself from hyponatremia through an intact thirst mechanism, conditions associated with alteration in thirst mechanism are more prone to induce hyponatremia. For specific conditions, see
History.Hyponatremia rarely is caused by a deficient intake, except in infants fed with hypotonic fluids. The most common cause of hyponatremia in children is loss of sodium from the gastrointestinal (GI) tract. Diarrhea is responsible for most incidents of hyponatremia in children. Sodium loss also occurs via the kidneys. Diuretics are the most common culprit, followed by less common causes (eg, salt-losing nephritis, mineralocorticoid deficiency, cerebral salt-wasting syndrome).
Excessive antidiuretic hormone (ADH) secretion causes water retention and subsequent dilutional hyponatremia. Excessive secretion of ADH occurs in response to pain, nausea, vomiting, and morphine intake in postoperative patients and in children following spinal fusion. Excessive secretion of ADH can occur without physiologic stimuli (eg, increased serum osmolality, decreased intravascular volume); hence, the condition is named syndrome of inappropriate secretion of ADH (SIADH). Some drugs (eg, vincristine) also can cause SIADH. In patients with cirrhosis, cardiac failure, or renal failure, hyponatremia may be caused by one of many mechanisms.
Clinical manifestations vary from asymptomatic to severe neurologic dysfunction. CNS symptoms predominate in hyponatremia, although cardiovascular and musculoskeletal findings also are present. Three factors contribute to CNS symptoms as follows:
1. Rate of change in serum sodium
2. Level of serum sodium
3. Duration of the abnormal serum sodium level
The gradual change in serum sodium, such as that observed with chronic hyponatremia, may not result in neurologic dysfunction even at serum sodium levels less than 100 mEq/L.
Central nervous system
When serum sodium declines, the decrease in serum osmolality results in an osmotic gradient across the blood-brain barrier causing water to move into the brain intracellular space. The resultant edema is responsible for symptoms such as headache, nausea, vomiting, irritability, and seizures. Animal studies have demonstrated that the brain swells only as much as 46% of the predicted level for a particular level of serum sodium when compared to other tissues after 6 hours of hyponatremia. This discrepancy becomes greater with time. This response of brain tissue indicates a significant degree of adaptation to hypo-osmolality. Thus, the subsequent amount of brain swelling is less than expected when considering osmotic gradient alone. The brain's adaptation to hyponatremia is accomplished by 2 mechanisms as follows:
1. Loss of interstitial fluid into the cerebrospinal fluid
2. Loss of cellular solute and organic osmolytes
When water moves into the brain, increasing hydrostatic pressure shifts interstitial fluid into cerebrospinal fluid, which subsequently is absorbed through the arachnoid villi. The interstitial fluid is rich in sodium, and, by removing this fluid, the brain equilibrates the osmolal gradient. In addition, intracellular solutes (eg, potassium) act similarly with a maximal response occurring in 24 hours. If hyponatremia lasts longer, intracellular amino acids extrude to maintain the osmolar gradient. This shifting of solutes and organic osmolytes plays an important role in protecting the brain from cerebral edema. The resultant hypo-osmolar state makes the brain vulnerable to dehydration secondary to rapid correction of hyponatremia. The optimum speed of correction is not known; however, rapid correction in fully compensated chronic hyponatremia results in a demyelinating lesion in the pons known as central pontine myelinosis (CPM). However, rapid correction in acute hyponatremia is well tolerated.
Cardiovascular response
Arterial blood volume may be increased, decreased, or normal depending on the underlying clinical condition. Intravascular volume is determined by distribution of water and solute in the intracellular space and extracellular space. Fluid shifts from extracellular space into intracellular space with a subsequent decrease in arterial blood volume. This may result in hypotension. Because of this fluid shift, hyponatremia causes more pronounced hemodynamic disturbance for a particular degree of dehydration.
Frequency:
In the US: Frequency is 1.5% of hospitalized pediatric patients.
Sex: Incidence of hyponatremia is equal in both sexes; however, CNS complications are more likely among females who are menstruating
Clinical
History:
Infants fed with hypotonic formula or free water
Conditions causing GI fluid loss, such as through the following:
Diarrhea
Vomiting
Fistulas
Renal disorders, including the following:
Salt-losing nephropathy
Acute renal failure
Chronic renal failure
Postoperative states
Psychiatric conditions
Coma
Drug use
CNS and pulmonary diseases
Hypothyroidism
Adrenal insufficiency
Cirrhosis
Congestive heart failure
Acquired immune deficiency syndrome
Physical:
Central nervous system
Early signs include the following:
Anorexia
Headache
Nausea
Emesis Advanced signs include the following: Impaired response to verbal stimuli
Impaired response to painful stimuli
Bizarre behavior
Hallucinations
Obtundation
Incontinence
Respiratory insufficiency Far-advanced signs include the following: Decorticate or decerebrate posturing
Bradycardia
Hypertension or hypotension
Altered temperature regulation
Dilated pupils
Seizure activity
Respiratory arrest
Coma Cardiovascular Hypotension Renal failure as consequence of hypotension Tachycardia Musculoskeletal Weakness Muscular cramps Causes: Hypervolemic hyponatremia Congestive heart failure Cirrhosis Nephrotic syndrome Acute or chronic renal failure Hypovolemic hyponatremia due to renal loss Diuretic excess Osmotic diuresis Salt-wasting diuresis Adrenal insufficiency
Proximal renal tubular acidosis
Metabolic alkalosis
Pseudohypoaldosteronism Hypovolemic hyponatremia due to extrarenal loss GI conditions, such as the following: Vomiting
Diarrhea
Tubes
Fistula Sweat Third-spacing conditions, such as the following: Pancreatitis
Burns
Muscle trauma
Peritonitis
Effusions
Ascites Normovolemic hyponatremia SIADH Tumors (ie, adenocarcinoma of duodenum, adenocarcinoma of
pancreas, carcinoma of ureter, carcinoma of prostate, Hodgkin disease,
thymoma, acute leukemia, lymphosarcoma, histiocytic lymphoma)
Chest disorders (ie, infection [tuberculosis, bacterial,
mycoplasmal, viral, fungal]), positive pressure ventilation, decreased
left atrial pressure [pneumothorax, atelectasis, asthma, cystic fibrosis,
mitral valve commissurotomy, patent ductus arteriosus ligation],
malignancy)
Central nervous system disorders (ie, infection [tuberculous
meningitis, bacterial meningitis, encephalitis], trauma, hypoxia-ischemia,
psychosis, brain tumor, miscellaneous [Guillain-Barré syndrome,
ventriculoatrial shunt obstruction, acute intermittent porphyria,
cavernous sinus thrombosis, multiple sclerosis, anatomic abnormalities,
vasculitis, stress, idiopathic])
Drugs (ie, chlorpropamide, vincristine, vinblastine,
diuretics, clofibrate, carbamazepine, fluphenazine, amitriptyline,
morphine, isoproterenol, nicotine, adenine arabinoside, colchicine,
barbiturates) Reset osmostat Glucocorticoid deficiency Hypothyroidism Water intoxication due to intravenous (IV) therapy, tap
water enema, or psychogenic water drinking
Lab Studies:
Verify accuracy of laboratory results.
Exclude pseudohyponatremia.
Flame emission spectrophotometry
If the sodium measurement is performed using flame
emission spectrophotometry, hyponatremia is falsely low in patients with
hyperproteinemia and hypertriglyceridemia.
Raised proteins and lipids increase the nonaqueous portion
of plasma, which normally comprises 7% of the plasma.
Flame photometry measures the concentration of sodium
present only in the aqueous portion of plasma.
However, newer ion-specific sodium electrodes measure
sodium from the aqueous phase only, which reduces the likelihood of
pseudohyponatremia. Correction factors for raised proteins and lipids Triglycerides (mg/dL) X .002 = mEq/L decrease in plasma
sodium (Plasma protein level [g/dL] - 8) X 0.25 = mEq decrease in
plasma sodium Each 100-mg/dL rise in glucose greater than the serum
glucose level of 100 mg/dL = 1.6 mEq/L decrease in sodium Exclude distributive hyponatremia: This condition occurs when
plasma glucose concentration exceeds 100 mg/dL. Obtain routine laboratory studies. Serum sodium Serum osmolality BUN and creatinine Urine osmolality Urine sodium Urine sodium level changes according to the type of
hyponatremia as follows: Hypovolemic hyponatremia Renal losses caused by diuretic excess, osmotic diuresis,
salt-wasting nephropathy, adrenal insufficiency, proximal renal tubular
acidosis, metabolic alkalosis, and pseudohypoaldosteronism result in a
urine sodium concentration greater than 20 mEq/L.
Extrarenal losses caused by vomiting, diarrhea, sweat, and
third spacing result in a urine sodium concentration less than 20 mEq/L. Normovolemic hyponatremia: When hyponatremia is caused by
SIADH, reset osmostat, glucocorticoid deficiency, hypothyroidism, or water
intoxication, urine sodium concentration is greater than 20 mEq/L. Hypervolemic hyponatremia If hyponatremia is caused by an edema-forming state (eg,
congestive heart failure, cirrhosis, nephrotic syndrome), urine sodium
concentration is less than 20 mEq/L.
If hyponatremia is caused by acute or chronic renal
failure, urine sodium concentration is greater than 40 mEq/L. Special laboratory studies include the following: Aldosterone Cortisol Thyroid function tests Adrenocorticotropic hormone
ADH Imaging Studies: Neuroimaging Skull radiographs: These images reveal intracranial
pathology (eg, calcification, sutural diastasis, bone defects). CT scan CT scan is much more sensitive and specific than skull
radiographs in delineating intracranial pathology.
CT scan is superior to MRI in delineating hemorrhage and
calcifications.
Intracranial calcifications, intracranial tumor,
hydrocephalus, and intracranial hemorrhage may be observed. MRI: MRI is more sensitive than CT scan in detecting tumors. Abdominal imaging Ultrasound: Ultrasound may reveal an abdominal mass in
individuals with bilateral adrenal hyperplasia and adrenal tumor. CT scan and MRI: These tests further delineate the tumor
Medical Care:
Principles of treatment
The most common and devastating effects of hyponatremia are of CNS origin. Therefore, being aware of the risk factors that lead to hyponatremia is very important; recognizing and treating the condition appropriately is also very important.
Although it occurs slowly, an adaptation mechanism in the
brain prevents deleterious effects of hypo-osmolality. However, this
protective mechanism leaves the brain susceptible to dehydration during
treatment, especially in persons with chronic hyponatremia, if the
correction is rapid.
In children who present with acute hyponatremic seizures due
to water intoxication from dilute formulas or excessive free water intake,
obtaining a history of such intake is important. Once the diagnosis is
reasonably certain, and even before laboratory data are available, correct
hyponatremia with IV bolus of 3% sodium chloride. Generally, seizures
resulting from acute water intoxication are not responsive to antiepileptic
drugs; however, such seizures respond very well to 3% sodium chloride.
Consider IV furosemide to increase water excretion.
In patients with chronic hyponatremia, correcting the sodium
slowly is important to prevent potential demyelinating lesions. Optimal rate
of correction is 0.5 mEq/h, not to exceed serum sodium of 125 mEq/L. Correction of sodium deficit When using 3% sodium chloride to correct sodium deficit, use
the following calculation: Sodium deficit = Weight in kg X 0.6 X (125 - observed
sodium)
Each milliliter of 3% sodium chloride contains approximately
0.5 mEq Na/L. Administering 1 mL/kg of 3% sodium chloride raises the serum
sodium by 1.6 mEq.
Symptomatic hyponatremia In individuals with hypovolemic hyponatremia, administer 3%
sodium chloride to correct hyponatremia and 0.9% sodium chloride for
intravascular volume expansion.
In persons with normovolemic hyponatremia, administer 3%
sodium chloride to correct hyponatremia.
In persons with hypervolemic hyponatremia, administer 3%
sodium chloride to raise the sodium level. Asymptomatic hyponatremia In individuals with hypovolemic hyponatremia, use 0.9%
sodium chloride for replacement and maintenance therapy.
In persons with normovolemic hyponatremia, restrict fluids
(two-thirds maintenance or more) and administer diuretics (furosemide is
preferred).
In persons with hypervolemic hyponatremia, restrict fluids
(two-thirds maintenance or more). Consultations: Transfer patients with symptomatic hyponatremia to a pediatric
intensive care unit for appropriate treatment and close monitoring. Order an endocrinology consultation for patients with
hypothyroidism or adrenal insufficiency. Order a nephrology consultation for patients with salt-losing
nephropathies or renal failure. Diet: Patients with salt-wasting disorders (eg, salt-losing
nephropathies) need sodium supplementation throughout continued loss of
excessive sodium. Patients with SIADH and renal failure require fluid
restriction.
Medication
Medications include 3% sodium chloride (513 mEq/L sodium),
normal saline (154 mEq/L sodium), diuretics, and other drugs used in persons
with SIADH (eg, lithium carbonate, demeclocycline, ethanol, phenytoin,
vasopressin analogs).
Drug Category: Diuretics -- Promote excretion of water and electrolytes by kidneys. Used to treat heart failure or hepatic, renal, or pulmonary disease when sodium and water retention has resulted in edema or ascites. May be used as monotherapy or combination to treat hypertension.
Drug Name |
Furosemide (Lasix) -- Potent loop diuretic. Inhibits reabsorption of sodium and chloride in proximal and distal tubules and loop of Henle. High efficacy largely due to unique site of action. Action on distal tubule is independent of any possible inhibitory effect on either carbonic anhydrase or aldosterone. |
---|---|
Adult Dose |
20-80 mg PO qd; may repeat dose after
6-8h; titrate not to exceed 600 mg/d if necessary |
Pediatric Dose |
0.5-2 mg/kg/d PO divided q6-12h, not
to exceed 6 mg/kg/d |
Contraindications |
Documented hypersensitivity; hepatic coma; severe preexisting electrolyte imbalance (eg, hyponatremia, hypokalemia, hypocalcemia, hypochloremia, hypomagnesemia) |
Interactions |
Furosemide-induced electrolyte
disturbances (eg, hypokalemia, hypomagnesemia) can predispose patients to
digitalis toxicity |
Pregnancy |
C - Safety for use during pregnancy has not been established. |
Precautions |
Caution in diabetes mellitus,
ventricular arrhythmias, heart failure, potassium-losing nephropathy,
aldosterone excess, diarrhea, severe renal impairment (dosage adjustment),
and hyperuricemia |
Drug Category: Antidiuretic hormone inhibitors -- Produce diuresis by inhibition of ADH water reabsorption.
Drug Name |
Lithium (Eskalith, Lithobid) -- Inhibits renal response to ADH. |
---|---|
Adult Dose |
900-1200 mg PO divided tid/qid, not to exceed 2400 mg/d |
Pediatric Dose |
15-20 mg/kg/d PO divided tid/qid, not to exceed 2400 mg/d |
Contraindications |
Documented hypersensitivity; severe cardiovascular disease, renal impairment, or dehydration |
Interactions |
Potentiates effects of nondepolarizing
neuromuscular blockers |
Pregnancy |
D - Unsafe in pregnancy |
Precautions |
Although classified as pregnancy
category D, sometimes lithium therapy may be warranted during pregnancy;
however, warn patients about possible damage to fetus; if possible, withhold
during first trimester |
Drug Name |
Demeclocycline (Declomycin) -- Only tetracycline used in treatment of SIADH. Diuresis is produced by inhibition of ADH-induced water reabsorption in distal portion of convoluted tubules and collecting ducts of kidneys. Effects are observed within 5 d and are reversed within 2-6 d following cessation of therapy. |
---|---|
Adult Dose |
600-1200 mg PO divided tid/qid |
Pediatric Dose |
>8 years: 7-13 mg/kg PO divided bid/qid |
Contraindications |
Documented hypersensitivity; do not use in children <8 y |
Interactions |
Antacids reduce absorption; calcium
salts and magnesium salts present in foods and dairy products can form
chelates with tetracyclines and impair absorption |
Pregnancy |
D - Unsafe in pregnancy |
Precautions |
Caution in women who are breastfeeding |
Drug Name |
Phenytoin (Dilantin) -- Inhibits secretion of ADH. |
---|---|
Adult Dose |
Loading: 15-20 mg/kg PO/IV |
Pediatric Dose |
Administer as in adults |
Contraindications |
Documented hypersensitivity; sinoatrial block, second-degree and third-degree AV block, sinus bradycardia, or Adams-Stokes syndrome (unless pacemaker is present) |
Interactions |
Amiodarone, benzodiazepines,
chloramphenicol, cimetidine, fluconazole, isoniazid, metronidazole,
miconazole, phenylbutazone, succinimides, sulfonamides, omeprazole,
phenacemide, disulfiram, ethanol (acute ingestion), trimethoprim, and
valproic acid may increase toxicity |
Pregnancy |
D - Unsafe in pregnancy |
Precautions |
Caution in hematologic disease, dental
disease, intermittent porphyria, hepatic disease, renal failure, radiation
therapy, hypothyroidism, and systemic lupus erythematosus |
Prevention:
Avoid administering hypotonic fluids when the patient is experiencing diarrhea.
Carefully monitor patients receiving medications.
Monitor serum electrolytes regularly in patients with brain tumors, intracranial infections, pulmonary infections, head trauma, and in patients following surgery, especially in those undergoing spinal fusion.
Pay careful attention to fluid management in children with coma and other critical illnesses.
Complications:
CPM in patients with chronic hyponatremia
This condition most commonly is observed in prepubescent children and women who are menstruating.
During chronic hyponatremia, the CNS undergoes significant adaptation by losing intracellular osmolytes in order to maintain the equilibrium between the intracellular and extracellular compartment. This change prevents the development of hyponatremia and makes cells susceptible to dehydration during treatment, especially if significant osmolar change in the extracellular environment exists. The resultant dehydration predominantly affects pontine regions where gray and white matter fibers are mixed together, resulting in CPM.
A number of studies have demonstrated that cerebral demyelinating lesions develop only when patients with chronic hyponatremia have the following:
Inadvertent hyponatremia during treatment
An absolute increase in plasma sodium that exceeds 25 mmol/L
in the first 24-48 hours of therapy
Hypoxic event
Severe liver disease Clinical features of CPM include the following: Motor abnormalities that slowly progress to flaccid
paralysis
Cranial nerve abnormalities manifested as dysphagia or
pseudobulbar palsy
Alteration of mental status (eg, behavioral changes,
depression of sensorium, lethargy, coma)
Seizures (uncommon)
Condition usually fatal in 3-5 weeks (however, survival
increasingly reported, frequently with residual disability) MRI is superior to CT scan in CPM because MRI permits
visualization of the brain stem and is sensitive to alterations in white
matter. Lesions become apparent 1-2 weeks later. Patient Education: Advise parents not to replace diarrheal fluid loss with
hypotonic fluids such as tea and soda.
Legal Pitfalls:
Avoid rapid correction of chronic hyponatremia.
In persons with asymptomatic chronic hyponatremia, rapid correction may result in the severe neurologic impairment of CPM.
In individuals with acute symptomatic hyponatremia, initiate therapy with intravenous 3% sodium chloride, using an intravenous pump with the infusion designed to raise plasma sodium at a rate of approximately 1 mmol/L per hour until 125 mEq/L is reached. Following resolution of symptoms, correction can proceed at a slower rate.
Home page, Drug information's ,Regional anesthesia ,Index for diseases ,Index for diseases, Perioperative medicine, Search engine, Accreditation, Learn Arabic Warfare, Anesthesia LINKS, Orthopedic LINKS, Midline
Constructed by Dr N.A. Nematallah Consultant in perioperative medicine and intensive therapy, Al Razi Orthopedic Hospital , State of Kuwait, email : razianesth@freeservers.com